Open Access
Evidence for a role of nicotinic acetylcholine receptors in schizophrenia
Catherine E Adams1,Karen E Stevens1
Department of Psychiatry, Veterans Affairs Medical Center, Denver, CO 80220, USA.
DOI: 10.2741/2424 Volume 12 Issue 12, pp.4755-4772
Published: 01 May 2007
(This article belongs to the Special Issue Nicotinic acetylcholine receptors in adult and developing brain)

Schizophrenia is a debilitating, complex and costly illness affecting roughly 1% of the world's inhabitants. The excessive degree of cigarette smoking exhibited by schizophrenic patients suggests that they might be self-medicating to ameliorate certain aspects of the characteristic positive, negative and cognitive symptoms associated with the disease. Morphological examinations found alterations in nicotinic receptors in postmortem tissue from schizophrenic individuals compared to controls, especially in the a7 and a4b2 subtypes. These data were consistent with molecular biology studies which demonstrated associations between polymorphisms in gene coding for these receptors and schizophrenia. In studies of nicotinic receptor stimulation in schizophrenia patients, improvement in sensory inhibition and cognitive deficits were observed following treatment, though the effects were transient. These results have spurred the development of new pharmaceuticals specifically designed to modulate nicotinic receptor function. The initial results from clinical trials of these new drugs appear promising, potentially opening new avenues of treatment for this devastating disease.

Share and Cite
Catherine E Adams, Karen E Stevens. Evidence for a role of nicotinic acetylcholine receptors in schizophrenia. Frontiers in Bioscience-Landmark. 2007. 12(12); 4755-4772.